Predictive oncology completes ai-driven study of ovarian cancer with upmc magee-womens hospital

Pittsburgh, nov. 08, 2023 (globe newswire) -- predictive oncology inc. (nasdaq: poai), a leader in ai-driven drug discovery and biologics, announced today that it has completed a multi-year study with upmc magee-womens hospital. the objective of the study was to evaluate the use of ai to build multi-omic machine learning (ml) models and test if these models can learn associations between the datasets and ovarian cancer patient short- and long-term survival.
POAI Ratings Summary
POAI Quant Ranking